Neil  Kumar net worth and biography

Neil Kumar Biography and Net Worth

Neil Kumar, Ph.D. is a co-founder and has served as our Chief Executive Officer and a member of our Board of Directors since April 2015. Dr. Kumar has also served as the Chief Executive Officer of our subsidiary, Eidos Therapeutics, Inc. (formerly Nasdaq: EIDX), a clinical-stage biopharmaceutical company, and a member of Eidos Therapeutics’ board of directors since March 2016. Prior to that, he served as the interim vice president of business development at MyoKardia, Inc. (formerly Nasdaq: MYOK, acquired by Bristol Myers Squibb), a clinical-stage biopharmaceutical company, from 2012 to 2014. Prior to that, Dr. Kumar served as a principal at Third Rock Ventures, a venture capital firm, from 2011 to 2014. Before joining Third Rock Ventures, he served as an associate principal at McKinsey & Company, a worldwide management consulting firm, from 2007 to 2011. Dr. Kumar has served as a member of the board of directors of LianBio (Nasdaq: LIAN) since October 2019. He received his B.S. and M.S. degrees in chemical engineering from Stanford University and received his Ph.D. in chemical engineering from the Massachusetts Institute of Technology. Dr. Kumar’s qualifications to serve on our Board of Directors include his role as our principal executive officer and his extensive experience as an executive officer of biotechnology companies.

What is Neil Kumar's net worth?

The estimated net worth of Neil Kumar is at least $156.53 million as of August 17th, 2023. Dr. Kumar owns 4,813,197 shares of BridgeBio Pharma stock worth more than $156,525,166 as of December 10th. This net worth estimate does not reflect any other assets that Dr. Kumar may own. Additionally, Dr. Kumar receives a salary of $2,100,000.00 as CEO at BridgeBio Pharma. Learn More about Neil Kumar's net worth.

How old is Neil Kumar?

Dr. Kumar is currently 44 years old. There are 7 older executives and no younger executives at BridgeBio Pharma. Learn More on Neil Kumar's age.

What is Neil Kumar's salary?

As the CEO of BridgeBio Pharma, Inc., Dr. Kumar earns $2,100,000.00 per year. Learn More on Neil Kumar's salary.

How do I contact Neil Kumar?

The corporate mailing address for Dr. Kumar and other BridgeBio Pharma executives is 421 Kipling Street, Palo Alto CA, 94301. BridgeBio Pharma can also be reached via phone at (650) 391-9740. Learn More on Neil Kumar's contact information.

Has Neil Kumar been buying or selling shares of BridgeBio Pharma?

Neil Kumar has not been actively trading shares of BridgeBio Pharma over the course of the past ninety days. Most recently, Neil Kumar sold 51,552 shares of the business's stock in a transaction on Thursday, August 17th. The shares were sold at an average price of $28.59, for a transaction totalling $1,473,871.68. Following the completion of the sale, the chief executive officer now directly owns 4,813,197 shares of the company's stock, valued at $137,609,302.23. Learn More on Neil Kumar's trading history.

Who are BridgeBio Pharma's active insiders?

BridgeBio Pharma's insider roster includes Douglas Dachille (Director), Ronald Daniels (Director), Neil Kumar (CEO), Richard Scheller (Insider), and Brian Stephenson (CFO). Learn More on BridgeBio Pharma's active insiders.

Are insiders buying or selling shares of BridgeBio Pharma?

In the last year, insiders at the sold shares 15 times. They sold a total of 2,432,998 shares worth more than $64,577,549.43. The most recent insider tranaction occured on August, 17th when CFO Brian C Stephenson sold 22,683 shares worth more than $648,506.97. Insiders at BridgeBio Pharma own 28.5% of the company. Learn More about insider trades at BridgeBio Pharma.

Information on this page was last updated on 8/17/2023.

Neil Kumar Insider Trading History at BridgeBio Pharma

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
8/17/2023Sell51,552$28.59$1,473,871.684,813,197View SEC Filing Icon  
5/17/2023Sell51,552$14.01$722,243.524,813,197View SEC Filing Icon  
4/5/2023Sell120,000$15.46$1,855,200.001,132,722View SEC Filing Icon  
3/3/2023Sell120,000$10.96$1,315,200.001,252,722View SEC Filing Icon  
2/17/2023Sell44,798$12.70$568,934.604,813,197View SEC Filing Icon  
2/3/2023Sell120,000$11.01$1,321,200.001,372,722View SEC Filing Icon  
1/5/2023Sell120,000$7.67$920,400.001,492,722View SEC Filing Icon  
11/17/2022Sell34,640$9.40$325,616.004,813,197View SEC Filing Icon  
8/3/2020Sell66,057$27.27$1,801,374.394,685,725View SEC Filing Icon  
7/1/2020Sell87,025$31.09$2,705,607.254,685,725View SEC Filing Icon  
6/3/2020Sell5,930$30.05$178,196.504,685,725View SEC Filing Icon  
5/5/2020Sell79,600$31.02$2,469,192.004,685,725View SEC Filing Icon  
4/7/2020Sell1,805$25.48$45,991.404,685,725View SEC Filing Icon  
4/3/2020Sell300$25.09$7,527.004,685,725View SEC Filing Icon  
4/1/2020Sell62,117$26.26$1,631,192.424,685,725View SEC Filing Icon  
2/5/2020Sell30,893$34.87$1,077,238.914,685,365View SEC Filing Icon  
See Full Table

Neil Kumar Buying and Selling Activity at BridgeBio Pharma

This chart shows Neil Kumar's buying and selling at BridgeBio Pharma by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

BridgeBio Pharma Company Overview

BridgeBio Pharma logo
BridgeBio Pharma, Inc. engages in the discovery, development, and delivery of various medicines for genetic diseases. The company has a pipeline of 30 development programs that include product candidates ranging from early discovery to late-stage development. Its products in development programs include AG10 and BBP-265, a small molecule stabilizer of transthyretin, or TTR that is in Phase 3 clinical trial for the treatment of TTR amyloidosis-cardiomyopathy, or ATTR-CM; BBP-831, a small molecule selective FGFR1-3 inhibitor, which is Phase 2 clinical trial to treat achondroplasia in pediatric patients; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD. The company also develops Encaleret, a small molecule antagonist of the calcium sensing receptor, or CaSR, which is in phase 2 proof-of-concept clinical trial for Autosomal Dominant Hypocalcemia Type 1, or ADH1; and BBP-711 for the treatment of hyperoxaluria, as well as patients suffering from recurrent kidney stones. In addition, it engages in developing products for Mendelian, oncology, and gene therapy diseases. BridgeBio Pharma, Inc. has license and collaboration agreements with the Leland Stanford Junior University; and The Regents of the University of California; Leidos Biomedical Research, Inc. The company was founded in 2015 and is headquartered in Palo Alto, California.
Read More

Today's Range

Now: $32.52
Low: $32.16
High: $34.49

50 Day Range

MA: $27.60
Low: $24.02
High: $33.61

2 Week Range

Now: $32.52
Low: $6.64
High: $36.36


1,256,112 shs

Average Volume

1,210,118 shs

Market Capitalization

$5.66 billion

P/E Ratio


Dividend Yield